Announcements Trials
Browse Landscape

Phase

Phase 1 6

Status

Completed 6

Sponsor Class

INDUSTRY 6NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 10Gastrointestinal 7Tumor-Agnostic 6Gynecologic 4Genitourinary 4Other solid neoplasm 2

Conditions

Neoplasms 6

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × nintedanib × Tumor-Agnostic × Clear all
NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
30 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT00998296 2015-08-19

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Boehringer Ingelheim

Phase 1 Completed
70 enrolled 25 charts
Tumor-Agnostic

Neoplasms

NCT00715403 2014-12-02

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Boehringer Ingelheim

Phase 1 Completed
41 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT02182128 2014-07-18

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT02182206 2014-07-18

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡